Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis

Galectin-3 is an important modulator of several biological functions. It has been implicated in numerous disease conditions, particularly in the long-term complications of diabetes because of its ability to bind the advanced glycation/lipoxidation end products that accumulate in target organs and exert their toxic effects by triggering proinflammatory and prooxidant pathways. Recent evidence suggests that galectin-3 may also participate in the development of obesity and type 2 diabetes. It has been shown that galectin-3 levels are higher in obese and diabetic individuals and parallel deterioration of glucose homeostasis. Two studies in galectin-3 knockout mice fed a high-fat diet (HFD) have shown increased adiposity and adipose tissue and systemic inflammation associated with altered glucose homeostasis, suggesting that galectin-3 negatively modulates the responsiveness of innate and adaptive immunity to overnutrition. However, these studies have also shown that impaired glucose homeostasis occurs in galectin-3 knockout animals independently of obesity. Moreover, another study reported decreased weight and fat mass in HFD-fed galectin-3 knockout mice. In vitro, galectin-3 was found to stimulate differentiation of preadipocytes into mature adipocytes. Altogether, these data indicate that galectin-3 deserves further attention in order to clarify its role as a potential player and therapeutic target in obesity and type 2 diabetes.

[1]  A. Sherman,et al.  Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis , 2007, Diabetologia.

[2]  J. Dennis,et al.  Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation , 2001, Nature.

[3]  E. Malchiodi,et al.  Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. , 2014, International journal of cardiology.

[4]  Z. Størling,et al.  Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. , 2006, Biochemical and biophysical research communications.

[5]  J. R. Menezes,et al.  Lack of galectin‐3 speeds Wallerian degeneration by altering TLR and pro‐inflammatory cytokine expressions in injured sciatic nerve , 2013, The European journal of neuroscience.

[6]  G. Pugliese,et al.  Role of galectin-3 in diabetic nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[7]  Ann Marie Schmidt,et al.  The growing problem of obesity: mechanisms, consequences, and therapeutic approaches. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Merlin C. Thomas,et al.  High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. , 2005, Journal of molecular endocrinology.

[9]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[10]  T. Yoshii,et al.  CD 29 and CD 7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis , 2003 .

[11]  Riyao Yang,et al.  Expression of galectin-3 modulates T-cell growth and apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Marsden.  I and J , 2012 .

[13]  S. Barondes,et al.  Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.

[14]  Y. Zou,et al.  RAGE Regulates the Metabolic and Inflammatory Response to High-Fat Feeding in Mice , 2014, Diabetes.

[15]  Jack Gauldie,et al.  Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. , 2012, American journal of respiratory and critical care medicine.

[16]  John L. Wang,et al.  Intracellular functions of galectins. , 2002, Biochimica et biophysica acta.

[17]  R. Hughes,et al.  Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. , 1999, European journal of biochemistry.

[18]  J. Dennis,et al.  N-Acetylglucosaminyltransferase V (Mgat5)-Mediated N-Glycosylation Negatively Regulates Th1 Cytokine Production by T Cells1 , 2004, The Journal of Immunology.

[19]  J. Dennis,et al.  Regulation of Cytokine Receptors by Golgi N-Glycan Processing and Endocytosis , 2004, Science.

[20]  K. Blomgren,et al.  Microglia-Secreted Galectin-3 Acts as a Toll-like Receptor 4 Ligand and Contributes to Microglial Activation. , 2015, Cell reports.

[21]  Masahiko Kato,et al.  Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus , 2014, Diabetology & Metabolic Syndrome.

[22]  J. Schölmerich,et al.  Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. , 2010, The Journal of clinical endocrinology and metabolism.

[23]  R. Ramasamy,et al.  Mechanisms of Disease: advanced glycation end-products and their receptor in inflammation and diabetes complications , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[24]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[25]  G. Fantuzzi,et al.  Increased Adiposity, Dysregulated Glucose Metabolism and Systemic Inflammation in Galectin-3 KO Mice , 2013, PloS one.

[26]  J. Levine,et al.  Galectin‐3 Stimulates Preadipocyte Proliferation and Is Up‐regulated in Growing Adipose Tissue , 2007, Obesity.

[27]  S. Menini,et al.  Galectin-3: an emerging all-out player in metabolic disorders and their complications. , 2015, Glycobiology.

[28]  Mirna Flögel,et al.  Galectin-3: an open-ended story. , 2006, Biochimica et biophysica acta.

[29]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[30]  J. Dennis,et al.  Metabolism, Cell Surface Organization, and Disease , 2009, Cell.

[31]  S. Menini,et al.  Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. , 2011, Journal of hepatology.

[32]  E. Ravussin,et al.  Effect of 8 Weeks of Overfeeding on Ectopic Fat Deposition and Insulin Sensitivity: Testing the “Adipose Tissue Expandability” Hypothesis , 2014, Diabetes Care.

[33]  S. Forbes,et al.  Regulation of Alternative Macrophage Activation by Galectin-31 , 2008, The Journal of Immunology.

[34]  M. Çakmak,et al.  Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? , 2015, Journal of Endocrinological Investigation.

[35]  T. Yoshii,et al.  CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. , 2003, Cancer research.

[36]  N. Arsenijević,et al.  Galectin-3 Deficiency Accelerates High-Fat Diet–Induced Obesity and Amplifies Inflammation in Adipose Tissue and Pancreatic Islets , 2013, Diabetes.

[37]  J. Iredale,et al.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Hsu,et al.  Galectin-3 Is a Negative Regulator of Lipopolysaccharide-Mediated Inflammation1 , 2008, The Journal of Immunology.

[39]  S. Park,et al.  Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea. , 2005, Metabolism: clinical and experimental.

[40]  John L. Wang,et al.  Identification of galectin-3 as a factor in pre-mRNA splicing. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  G. Pugliese.  Do advanced glycation end products contribute to the development of long-term diabetic complications? , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[42]  Robert G. Parton,et al.  Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers , 2014, Nature Cell Biology.

[43]  H. Kuwano,et al.  Implication of galectin-3 in Wnt signaling. , 2005, Cancer research.

[44]  A. Vidal-Puig,et al.  Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome--an allostatic perspective. , 2010, Biochimica et biophysica acta.

[45]  C. Horikawa,et al.  Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta‐analysis , 2014, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[46]  E. Telemo,et al.  Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. , 2008, Glycobiology.

[47]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[48]  Lu-Gang Yu,et al.  Galectin-3--a jack-of-all-trades in cancer. , 2011, Cancer letters.

[49]  N. Arsenijević,et al.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. , 2009, Clinical immunology.

[50]  R. Hughes.  Galectins as modulators of cell adhesion. , 2001, Biochimie.

[51]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[52]  Seok-Jun Kim,et al.  Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. , 2015, Endocrinology.

[53]  D. Henning.  Metabolism , 1972, Introduction to a Phenomenology of Life.

[54]  Stephen Colagiuri,et al.  Grand challenges in chronic non-communicable diseases , 2007, Nature.

[55]  S. Menini,et al.  Galectin-3 in diabetic patients , 2014, Clinical chemistry and laboratory medicine.

[56]  D. Mutch,et al.  Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  A. Schmidt,et al.  Glycation and insulin resistance: novel mechanisms and unique targets? , 2012, Arteriosclerosis, thrombosis, and vascular biology.